Leishmaniasis: Current status of vaccine development

Clinical Microbiology Reviews

Volumn 14, Issue 2, 2001, Pages 229-243

  Handman, E ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMPHOTERICIN B LIPID COMPLEX; ANTIMONY DERIVATIVE; BACTERIAL DNA; CYTOKINE; DNA VACCINE; IMMUNOLOGICAL ADJUVANT; KETOCONAZOLE; LEISHMANIA VACCINE; LIVE VACCINE; PAROMOMYCIN; PROTOZOAL DNA; RECOMBINANT ANTIGEN; SYNTHETIC PEPTIDE; VIRULENCE FACTOR;

ARTICLE; DNA SEQUENCE; DRUG DELIVERY SYSTEM; HELPER CELL; HOST SUSCEPTIBILITY; HUMAN; IMMUNOSTIMULATION; NONHUMAN; PATHOGENESIS; SKIN LEISHMANIASIS; VACCINATION; VACCINE PRODUCTION; VISCERAL LEISHMANIASIS;

ANIMALS; HISTORY, 20TH CENTURY; HUMANS; LEISHMANIA; LEISHMANIASIS; PROTOZOAN VACCINES;

ANIMALIA; BACTERIA (MICROORGANISMS); PROTOZOA;

EID: 0035067363     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.14.2.229-243.2001     Document Type: Article

References (157)

1. Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice
2. Subunit vaccination of mice against new world cutaneous leishmaniasis: Comparison of three proteins expressed in amastigotes and six adjuvants
3. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes
4. Human dendritic cell (DC)-based anti-infective therapy: Engineering DCs to secrete functional IFN-gamma and IL-12
5. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection
6. DNA vaccines: Technology and application as anti-parasite and anti-microbial agents
7. A radioattenuated Leishmania major vaccine markedly increases the resistance to CBA mice to subsequent infection with Leishmania mexicana mexicana
8. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response
9. Visceral leishmaniasis: Another HIV-associated opportunistic infection? Report of eight new cases and review of the literature
10. Leishmaniasis and AIDS co-infection: The Spanish example
11. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: Safety, immunogenicity, and efficacy during the first 12 months of follow-up
12. Leishmania donovani: An opportunistic microbe associated with progressive disease in three immunocompromised patients
13. Dendritic cells and the control of immunity
14. Cutaneous leishmaniasis (oriental sore). IV. Vaccination against oriental sore with suspensions of killed Leishmania tropica
15. Genetic regulation of leishmanial and mycobacterial infections: The Lsh/Ity/Bcg gene story continues
16. Structure and function of the natural-resistance-associated macrophage protein (Nramp1), a candidate protein for infectious and autoimmune disease susceptibility
17. Genetic susceptibility to leishmanial infections: Studies in mice and man
18. Parasite genome analysis. Progress in the Leishmania genome project
19. The multiplex function of nitric oxide in (auto)immunity
20. Genetic control of natural resistance to Leishmania donovani
21. Lsh: Origins and growth of a cottage industry
22. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: The generation of beneficial, potentially harmful, harmful and potentially extremely harmful states
23. Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients
24. Cloning and expression of a Leishmania donovani gene industructed by a peptide isolated from major histocompatibility complex class II molecules of infected macrophages
25. Cell-mediated immunity in localized cutaneous leishmaniasis patients before and after treatment with immunotherapy or chemotherapy
26. Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I. Skin-test reactivity, T-cell proliferation and interferon-gamma production
27. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection
28. New developments in the chemotherapy of leishmaniasis
29. Molecular determinants of Leishmania virulence
30. Plasmodium and Leishmania: The role of mdr genes in mediating drug resistance
31. Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands
32. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells
33. Advances in adjuvant technology and application
34. Adjuvants - A classification and review of their modes of action
35. Naked antigen-presenting molecules on dendritic cells
36. A method for the isolation and analysis of leucocytic cells from leishmanial ear lesions in mice
37. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis
38. DNA vaccines
39. Organ-specific immune responses associated with infectious disease
40. The geometry of synthetic peptide-based immunogens affects the efficiency of T cell stimulation by professional antigen-presenting cells
41. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene
42. Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine
43. The present and future of vaccination for cutaneous leishmaniasis
44. A reverse genetics approach to Bcg/Ity/Lsh gene cloning
45. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
46. DNA vaccines: A key for inducing long-term cellular immunity
47. Isolation and characterization of infective and non-infective clones of Leishmania tropica
48. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis
49. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response
50. Nucleic acid immunization: Concepts and techniques associated with third generation vaccines
51. 1 interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis
52. New and improved vaccines against pertussis
53. Experimental models for leishmaniasis and for testing anti-leishmanial vaccines
54. Assessment of inactivated influenza-A vaccine after three outbreaks of influenza A at Christ's Hospital
55. Prophylactic immunization against experimental leishmaniasis. I. Protection induced in mice genetically vulnerable to fatal Leishmania tropica infection
56. Prophylactic immunization against experimental leishmaniasis. III. Further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes
57. Restrictions on the use of antigenic peptides by the immune system
58. Parasite genome analysis. A global map of the Leishmania major genome: Prelude to genomic sequencing
59. Lipophosphoglycan and secreted acid phosphatase of Leishmania tropica share species-specific epitopes
60. Immunoprotective Leishmania major synthetic T cell epitopes
61. Immunoprotective Leishmania major synthetic T cell epitopes
62. Resistance to Leishmania major induced by tolerance to a single antigen
63. Strategies for immune intervention in visceral leishmaniasis
64. Genetic transformation of parasitic protozoa
65. Changes in virulence of strains of Leishmania tropica major
66. Problems and current lines in investigations on the epidemiology of leishmaniasis and its control in the USSR
67. Th1 and Th2 subsets: Paradigms lost?
68. Cytokines: Principles and prospects
69. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis
70. Inhibition of T cell proliferation by antibodies to synthetic peptides
71. Immunogenetics of human American cutaneous leishmaniasis. Study of HLA haplotypes in 24 families from Venezuela
72. Immune responses in vaccinated dogs with autoclaved Leishmania major promastigotes
73. The outcome of the parasitic process initiated by Leishmania infantum in laboratory mice: A tissue-dependent pattern controlled by the Lsh and MHC loci
74. Tumor necrosis factor-α synergizes with IFN-γ mediating killing of Leishmania major through the induction of nitric oxide
75. Molecular cloning and characterization of the immunologically protective surface glycoprotein GP46/M-2 of Leishmania amazonensis
76. Major histocompatibility complex genotype is associated with disease progression and virus load levels in a cohort of human immunodeficiency virus type 1-infected Caucasians and African Americans
77. Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil
78. An innate sense of danger
79. Leishmania enriettii immune induction of macrophage activation in an experimental model of immunoprophylaxis in the mouse
80. A field trial of a vaccine against American dermal leishmaniasis
81. Further trials of a vaccine against American cutaneous leishmaniasis
82. Vaccination of dogs against Leishmania (Viannia) braziliensis
83. Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs
84. Lipophosphoglycan of Leishmania major that vaccinates against cutaneous leishmaniasis contains an alkylglycerophosphoinositol lipid anchor
85. WHO warns of epidemic leishmania
86. Loss of the GP46/M2 surface membrane glycoprotein gene family in the Leishmania braziliensis complex
87. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection
88. Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters
89. Analysis of the human T cell responsiveness to purified antigens of Leishmania: Lipophosphoglycan (LPG) and glycoprotein 63 (GP63)
90. Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis
91. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
92. Function and regulation of memory CD4 T cells
93. The glycoconjugate derived from a Leishmania major receptor for macrophages is a suppressogenic, disease-promoting antigen in murine cutaneous leishmaniasis
94. Vaccines against leishmaniasis
95. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran
96. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection
97. Changes in the precursor frequencies of IL-4 and IFN-γ secreting CD4+ cells correlate with resolution of lesions in murine cutaneous leishmaniasis
98. Interleukin-4 but not interferon-γ production correlates with the severity of disease in murine cutaneous leishmaniasis
99. Strategies involved in developing an effective vaccine for EBV-associated diseases
100. Expression cloning of a protective Leishmania antigen
101. Control of Leishmania major infection in mice lacking TNF receptors
102. Cultures des corps de Leishman isoles de la rate dans trois cas d'anemic sptenique infantile
103. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant Leishmania 'major surface glycoprotein' (gp63)
104. Antigen presentation by macrophages harboring intravesicular pathogens
105. Epidemiology, diagnosis and control of leishmaniasis in the Mediterranean region
106. ISCOMs vaccine against experimental leishmaniasis
107. Exposing the immunology of naked DNA vaccines
108. Enseaio sobre vacinacao preventiva na leishmaniose tegumentar americana com germenes mortos
109. Segunda nota sobre a vacinacao preventiva na leishmaniose tegumentar americana com leptomones mortas
110. Primary responses of human T cells to mycobacteria: A frequent set of γδ T cells are stimulated by protease-resistant ligands
111. Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocopatibility complex-restricted manner
112. Experimental cutaneous leishmaniasis. V. Protective immunity in subclinical and selfhealing infection in the mouse
113. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent Leishmania major challenge
114. Vaccination against Leishmania major in a CBA mouse model of infection: Role of adjuvants and mechanism of protection
115. Leishmaniasis in the new genetic era
116. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes
117. Human T cell responses to gp63, a surface antigen of Leishmania
118. Mapping human T cell epitopes in Leishmania gp63
119. An analysis of T cell responsiveness in Indian kala-azar
120. Immunological concepts of vaccine adjuvant activity
121. IL-12 as an adjuvant for cell-mediated immunity
122. DNA vaccines - Designer vaccines for the 21st century
123. Effect of leishmanial vaccinations on the dynamics of immunity to diphteria in conditions of secondary revaccination with adsorbed pertussis-diphteria-tetanus vaccine
124. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran
125. Evidence for human CD4+ T cells in the CD1-restricted repertoire: Derivation of mycobacteria-reactive T cells from leprosy lesions
126. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection
127. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response is required for generation of immunity to leishmaniasis
128. LeIF: A recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile
129. The host response to Leishmania infection
130. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis
131. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine
132. Macrophages ingest and are activated by bacterial DNA
133. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major
134. BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice
135. CD1 - A new paradigm for antigen presentation and T cell activation
136. Leishmaniasis in the Middle East
137. Effect of treatment with interferon-gamma alone in visceral leishmaniasis
138. Immunochemotherapy for a systemic intracellular infection: Accelerated response using interferon-gamma in visceral leishmaniasis
139. Inadequate epidermal homing leads to tissue damage in human cutaneous leishmaniasis
140. Development of a safe live Leishmania vaccine line by gene replacement
141. Multidrug resistance and P-glycoproteins in parasitic protozoa
142. DNA vaccines
143. A dhfr-ts- Leishmania major knockout mutant cross-protects against Leishmania amazonensis
144. Gene vaccines
145. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis
146. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms
147. The role of the major histocompatibility complex in resistance to parasite infections
148. AIDS, leishmaniasis dangers of clash highlighted
149. Advances in the battle against leishmaniasis
150. Exacerbation of dimorphous leprosy apparently due to BCG vaccination
151. Protection against Leishmania major infection in genetically susceptible BALB/c mice by GP63 delivered orally in attenuated Salmonella typhimurium (AroA-AroD-)
152. Protective effect on Leishmania major infection of migration inhibitory factor, TNF-alpha, and IFN-gamma administered orally via attenuated Salmonella typhimurium
153. In vitro augmentation of natural killer cell activity and production of interferon-alpha/beta and -gamma with deoxyribonucleic acid fraction from Mycobacterium bovis BCG
154. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis
155. Totally synthetic lipid-containing polyoxime peptide constructs are potent immunogens
156. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis